Showing results (91-100 of 128) with videos related to
Sort By:
Pageof 13
The New England Journal of Medicine|July 14, 2021
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseRobert Zeiser, Nicola Polverelli, Ron Ram, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2011
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantationRon Ram, Ted A Gooley, David G Maloney, et al.Haematologica|April 22, 2011
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemiaRon Ram, Rainer Storb, Brenda M Sandmaier, et al.The Lancet. Haematology|February 2, 2019
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 studyNoelle Frey, Jun Ho Jang, Jeff Szer, et al.Journal of Clinical Immunology|September 5, 2022
Clinically Complex LRBA Deficiency Due to a Founder Allele in the Georgian Jewish PopulationTal Freund, Sarah K Baxter, Tom Walsh, et al.Leukemia & Lymphoma|September 14, 2017
Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?Ohad S Bentur, Ronit Gurion, Anat Gafter-Gvili, et al.Haematologica|July 8, 2021
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort studyRon Ram, Sigal Grisariu, Liat Shargian-Alon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyRobert Zeiser, Domenico Russo, Ron Ram, et al.American Journal of Hematology|October 6, 2015
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemiaYishai Ofran, Ronit Leiba, Chezi Ganzel, et al.Blood Advances|November 27, 2019
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a studyTsila Zuckerman, Ron Ram, Luiza Akria, et al.Pageof 13